Health Care [ 10/12 ] | Health Care Equipment & Supplies [ 56/73 ]
NASDAQ | Common Stock
ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.
The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.
It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus.
ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -2.41 Decreased by -2.09 K% | - |
| Nov 6, 24 | -3.11 Decreased by -288.38% | - |
| Aug 14, 24 | -0.06 Increased by +94.44% | -0.12 Increased by +50.00% |
| May 15, 24 | -0.09 Increased by +94.23% | -0.16 Increased by +43.75% |
| Feb 23, 24 | -0.11 Increased by +98.72% | -0.18 Increased by +38.89% |
| Nov 8, 23 | -0.80 Increased by +96.92% | -1.20 Increased by +33.33% |
| Aug 7, 23 | -1.08 Increased by +95.68% | -1.79 Increased by +39.66% |
| May 15, 23 | -1.56 Increased by +92.91% | -4.21 Increased by +62.95% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 1.80 M Decreased by -7.15% | -1.76 M Increased by +19.70% | Decreased by -97.56% Increased by +13.52% |
| Dec 31, 24 | 1.80 M Decreased by -8.93% | -1.76 M Decreased by -3.71% | Decreased by -97.56% Decreased by -13.88% |
| Sep 30, 24 | 2.29 M Increased by +6.36% | -1.58 M Increased by +55.26% | Decreased by -68.98% Increased by +57.94% |
| Jun 30, 24 | 1.97 M Decreased by -12.82% | -1.59 M Increased by +54.34% | Decreased by -81.17% Increased by +47.62% |
| Mar 31, 24 | 1.94 M Decreased by -15.00% | -2.19 M Increased by +17.62% | Decreased by -112.81% Increased by +3.08% |
| Dec 31, 23 | 1.98 M Decreased by -36.27% | -1.70 M Increased by +89.78% | Decreased by -85.67% Increased by +83.96% |
| Sep 30, 23 | 2.15 M Decreased by -22.98% | -3.53 M Increased by +71.00% | Decreased by -163.99% Increased by +62.35% |
| Jun 30, 23 | 2.25 M Decreased by -22.06% | -3.49 M Increased by +63.01% | Decreased by -154.97% Increased by +52.54% |